RTP Mobile Logo
Select Publications

Krishna Gundabolu, MD

DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract

Swaminathan M et al. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Hematologica 2021;106(8):2121-30. Abstract

Wang ES et al. Preliminary data on a phase 1/2A first in human study of the Menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. ASH 2020;Abstract 115.

Wei AH et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 2020;135(24):2137-45. Abstract

Harry Paul Erba, MD, PhD

Döhner H et al. Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine for patients with acute myeloid leukemia in remission by disease subtype, cytogenetic risk, and npm1 mutation status at diagnosis. EHA 2021;Abstract S131.

Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract

Roboz GJ et al. CC-486 prolongs survival for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC) independent of the presence of measurable residual disease (MRD) at study entry: Results from the QUAZAR AML-001 maintenance trial. ASH 2020;Abstract 692.

Wei AH et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383:2526-37. Abstract

Eunice S Wang, MD

Alotaibi AS et al. Patterns of secondary resistance differ in patients (pts) with acute myeloid leukemia (AML) treated with type I versus type II FLT3-inhibitors (FLT3i’s). ASH 2020;Abstract 335.

DiNardo C et al. Updated pharmacodynamic and survival outcomes from the AG221-AML-005 trial of enasidenib (ena) plus azacitidine (aza) in patients with mutant IDH2 newly diagnosed acute myeloid leukemia (ND-AML). EHA 2021;Abstract EP465.

Konopleva M et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations. ASH 2020;Abstract 1904.

Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. ASCO 2021;Abstract 7012.

Pratz KW et al. A phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: Final results. ASH 2020;Abstract 24.

Krishna Gundabolu, MD

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Kubasch AS et al. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv 2021;5(5):1565-75. Abstract

Patel AA et al. Cedazuridine/decitabine: From preclinical to clinical development in myeloid malignancies. Blood Adv 2021;5(8):2264-71. Abstract

Venugopal S et al. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). ASCO 2021;Abstract 7010.